Skullcapflavone II (SkII) significantly alters serine metabolism in gastric cancer cells by directly targeting the L‐serine transporter SLC1A4, thereby inhibiting L‐serine uptake rather than de novo synthesis. This evidence concerns the gene SLC1A4 and gastric cancer.